↓ Skip to main content

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

Overview of attention for article published in British Journal of Cancer, December 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
20 Mendeley
Title
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
Published in
British Journal of Cancer, December 2018
DOI 10.1038/s41416-018-0354-9
Pubmed ID
Authors

Agostina Nardone, Hazel Weir, Oona Delpuech, Henry Brown, Carmine De Angelis, Maria Letizia Cataldo, Xiaoyong Fu, Martin J. Shea, Tamika Mitchell, Jamunarani Veeraraghavan, Chandandeep Nagi, Mark Pilling, Mothaffar F. Rimawi, Meghana Trivedi, Susan G. Hilsenbeck, Gary C. Chamness, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 20%
Student > Bachelor 3 15%
Unspecified 3 15%
Other 3 15%
Researcher 3 15%
Other 4 20%
Readers by discipline Count As %
Medicine and Dentistry 6 30%
Biochemistry, Genetics and Molecular Biology 5 25%
Unspecified 4 20%
Agricultural and Biological Sciences 3 15%
Chemistry 1 5%
Other 1 5%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 December 2018.
All research outputs
#3,566,512
of 13,118,813 outputs
Outputs from British Journal of Cancer
#3,249
of 8,035 outputs
Outputs of similar age
#115,407
of 320,767 outputs
Outputs of similar age from British Journal of Cancer
#42
of 64 outputs
Altmetric has tracked 13,118,813 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 8,035 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,767 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.